Biosimilars have been making substantial inroads in Europe, where their use is associated with increased patient access to treatment, particularly in nations with lower healthcare resources. Even so, biosimilars may be unfamiliar to stakeholders, and prescribers, pharmacists, and patients have lingering concerns about these products.
Biosimilars have been making substantial inroads in Europe, where their use is associated with increased patient access to treatment, particularly in nations with lower healthcare resources. Even so, biosimilars may be unfamiliar to stakeholders, and prescribers, pharmacists, and patients have lingering concerns about these products.
A recent survey was conducted among Polish pharmacists in general hospitals, and sought to assess attitudes toward and use of biosimilars in practice, and the results have been newly published in BioDrugs.1
The investigators distributed a paper-based, self-administered questionnaire to Polish hospital pharmacists and found that 77% of surveyed hospitals used biosimilars, while 90% used originator biologics.
The survey found that biosimilars comprise less than one-third of all biological therapy used in Polish hospitals, and 88% of surveyed pharmacists say that they are concerned that biosimilars are not identical to their reference products. Similarly, 48% of respondents are concerned about potential immunogenicity of biosimilars, and 44% have concerns about pharmacokinetic properties of these drugs.
The study’s authors conclude that, given the many concerns that stakeholders still have about biosimilar products, introducing these therapies into patient care requires special consideration. The authors call for improved legal regulation for biosimilars to help stakeholders feel more comfortable with understanding when and how biosimilars can be substituted for their reference products (Poland does not allow for unrestricted pharmacy-level substitution of biosimilars), improved communication between prescribers and pharmacists, and educational efforts to help improve the safe and effective use of biosimilars.
Improved use of biosimilars could have a positive impact on the Polish health system, which, like many healthcare systems in Eastern Europe, faces challenges related to its financial constraints. Last year, a paper published in Biomed Research International reported that, in Eastern Europe, numerous barriers stand between patients and biologic therapy. Among those barriers are volume limits on the number of patients who can be treated with biologics under public reimbursement, waiting lists for treatment (even in oncology indications), limited-duration biologic treatment, nonreimbursement of complementary diagnostics, and restricted reimbursement.2
References
1. Pawłowski I, Pawłowski L, Krzyżaniak N, Kocić I. Perspectives of hospital pharmacists towards biosimilar medicines: practice in general hospitals [published online March 4, 2019]. BioDrugs. doi: 10.1007/s40259-019-00341-w.
2. Inotai A, Csandi M, Petrova G, et al. Patient access, unmet medical need, expected benefits, and concerns related to the utilisation of biosimilars in Eastern European countries: a survey of experts [published online January 10, 2018]. Biomed Res Int. doi: 10.1155/2018/9597362.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
The Role of Biosimilars: Advancing Access, Financial Health, and System Sustainability
March 11th 2024Kashyap Patel, MD, CEO of Carolina Blood and Cancer Care, a member of the Community Oncology Alliance, and member of The Center for Biosimilars® Advisory Board, glances back at the development of the biosimilar industry and the last 5 years of progress.
Pipelines and Preparation: How the US Can Prepare for More RA Biosimilars
April 16th 2023What can practices do to prepare for all the biosimilars to treat rheumatoid arthritis (RA) coming down the pipeline? And how can they ensure that the lower-than-anticipated adoption rates for infliximab biosimilars are not repeated? Robert Zutaut, RPh, from McKesson Provider Solutions, tackles all this and more on this episode of Not So Different.
Cardinal Health Report Showcases Biosimilar Growth, Provider and Payer Evolution, and More
February 29th 2024In its annual biosimilars report, Cardinal Health provided updates on how provider acceptance growth, evolving payer dynamics, and the growing pipeline for biosimilars will shape the biosimilar landscape over the next 5 years.
Biosimilar Substitution Within OCM Could Result in Lower Total Cost of Care
February 16th 2024Researchers found that the total cost of care per oncology episode was significantly lowered when biosimilar substitution was implemented in Medicare’s Oncology Care Model (OCM), suggesting that biosimilar uptake can serve as a critical tool to mitigate risk and improve financial performance for providers.